Cisplatin for triple negative breast cancer

Author: jyls

August undefined, 2024

WebFeb 7, 2024 · Cisplatin is an old, platinum based anticancer drug that kills cancer cells by damaging their DNA. Its cytotoxic (cell-killing) properties were discovered by accident in … WebMar 22, 2024 · The addition of rucaparib to cisplatin did not increase 2-year DFS (54.2% cisplatin vs. 64.1% cisplatin + rucaparib; P = 0.29). ... Patients with triple-negative breast cancer (TNBC) who have ...

Efficacy of Neoadjuvant Cisplatin in Triple-Negative Breast Cancer ...

WebApr 1, 2024 · Triple-negative tumor cells, a malignant subtype of breast cancer, lack a biologically targeted therapy. Given its DNA repair inhibiting properties, caffeine has been shown to enhance the effectiveness of specific tumor chemotherapies. In this work, we have investigated the effects of caffeine, cisplatin, and a combination of the two as potential … WebJun 14, 2011 · Major Finding: Among patients with metastatic triple-negative breast cancers, single-agent therapy with cisplatin or carboplatin produced an overall response rate of 30.2%.Data Source: Multicenter prospective phase II trial by the Translational Breast Cancer Research Consortium.Disclosures: The stud dundee cotton hand towels

Cisplatin: a journey to a solution for triple-negative breast cancer

WebAug 29, 2012 · This is a Phase I dose escalation study of cisplatin and concurrent radiation in patients with ER negative, PR negative and HER2 negative breast cancer who have … WebJul 22, 2024 · Cisplatin represents a promising chemotherapeutic compound in neoadjuvant approaches and in the metastatic setting, but its use is limited by scarce bioavailability, severe systemic side effects and drug resistance. Novel site-directed aptamer-based nanotherapeutics have the potential to overcome obstacles of chemotherapy. WebFeb 25, 2024 · The Triple Negative Breast Cancer Trial (TNT) randomly assigned patients with metastatic TNBC to either docetaxel or carboplatin in the first-line treatment setting. 4 Results showed that carboplatin was … dundee cookery school

Epigenetic Priming with Decitabine Augments the Therapeutic

Cisplatin + RT for Triple Negative Breast Cancer - Full Text …

WebApr 3, 2024 · The chemotherapy reduces the risk of the breast cancer coming back. You usually have a combination of chemotherapy drugs that might include: doxorubicin epirubicin paclitaxel docetaxel carboplatin cisplatin Researchers are still looking into the best chemotherapy combinations. WebMar 31, 2024 · Triple-negative breast cancer (TNBC) is a heterogeneous group of breast cancers, characterized by lack of expression of estrogen receptors, progesterone receptors and human epidermal growth factor receptor 2 gene amplification, making it unresponsive to endocrine therapy and HER2-targeted treatment. dundee council available housingWebApr 8, 2024 · Stage 4 triple-negative breast cancer/triple-negative breast cancer metastasis: The initial treatment for patients with this type of cancer is usually chemotherapy. For those with triple-negative disease and a BRCA mutation, platinum-based therapies such as carboplatin or cisplatin may be used. dundee council adopted roads

"WebJun 6, 2024 · Patients with clinical stage II or III TNBC with ≥ 1 cm RD in the breast post-NAC were randomly assigned to receive platinum (carboplatin or cisplatin) once every 3 weeks for four cycles or capecitabine 14 out of 21 days every 3 weeks for six cycles. TNBC subtype (basal v nonbasal) was determined by PAM50 in the residual disease. " - Cisplatin for triple negative breast cancer

Cisplatin for triple negative breast cancer

Central Nervous System Metastases from Triple-Negative Breast Cancer ...

WebAug 29, 2013 · This is a phase II clinical trial of everolimus, an mTOR inhibitor, plus cisplatin chemotherapy in patients with triple negative breast cancer (TNBC) who have residual disease after completion of neoadjuvant chemotherapy. Everolimus and cisplatin will be administered for 12 weeks. Patients will undergo surgery after treatment completion. WebA triple combination gemcitabine + romidepsin + cisplatin to effectively control triple-negative breast cancer tumor development, recurrence, and metastasis Cancer Chemother Pharmacol. 2024 May 27. doi: 10.1007/s00280-021-04298-y. …

Did you know?

WebAug 1, 2024 · Purpose: Because of inherent disease heterogeneity, targeted therapies have eluded triple-negative breast cancer (TNBC), and biomarkers predictive of treatment response have not yet been identified. This study was designed to determine whether the mTOR inhibitor everolimus with cisplatin and paclitaxel would provide synergistic … WebJul 12, 2024 · Triple-negative breast cancer (TNBC), lacks the expression of estrogen receptor (ER) and progesterone-receptor (PgR) and amplification of human epidermal growth factor receptor 2 (HER2)...

WebJan 1, 2015 · No standard first-line treatment exists for patients with metastatic triple-negative breast cancer (mTNBC). In this single-arm, phase II study ( NCT00601159 ), … WebMay 25, 2024 · Methods: Patients (pts) with metastatic TNBC or g BRCA1/2- associated MBC, who had received < 1 line of prior therapy were treated with cisplatin (75mg/m2) plus Vel or P (300 mg po BID days 1-14), every 3 weeks. All …

WebJun 15, 2024 · Introduction. As one of the main causes of female deaths, breast cancer (BC) is a heterogeneous tumor with different subtypes [1,2].Triple negative breast … WebJan 25, 2010 · Cisplatin is a chemotherapeutic agent not used routinely for breast cancer treatment. As a DNA cross-linking agent, cisplatin may be effective treatment for …

WebJun 15, 2024 · Introduction. As one of the main causes of female deaths, breast cancer (BC) is a heterogeneous tumor with different subtypes [1,2].Triple negative breast cancer (TNBC) is the most invasive subtype with a relatively poor prognosis, because it lacks targeted therapies and has a low response to chemotherapy [3,4].Moreover, the disease …

WebJul 15, 2024 · Abstract Resistance to chemotherapy continues to be a critical issue in the clinical therapy of triple-negative breast cancer (TNBC). Epithelial-mesenchymal transition (EMT) is thought to contribute to chemoresistance in several … dundee council bus passWebTriple-negative breast cancer (TNBC) is a highly aggressive type of breast cancer lacking estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor2 (HER2), which resulted in the lack of target for treatment. 14 Up to date, drug treatment for triple-negative breast cancer still limited to cytotoxic agents such as ... dundee concerts feb 2023WebJan 25, 2010 · Cisplatin is a chemotherapeutic agent not used routinely for breast cancer treatment. As a DNA cross-linking agent, cisplatin may be effective treatment for hereditary BRCA1 -mutated breast cancers. dundee council education departmentWebCisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. dundee council bulky upliftWebApr 7, 2024 · The high frequency of homologous recombination deficiency (HRD) is the main rationale of testing platinum-based chemotherapy in triple-negative breast cancer (TNBC), however, the existing methods ... dundee council e learningWebNov 13, 2013 · Cisplatin and paclitaxel are active in triple-negative breast cancer (TNBC). Despite different mechanisms of action, effective predictive biomarkers to preferentially … dundee coney island dundee miWebApr 7, 2024 · The high frequency of homologous recombination deficiency (HRD) is the main rationale of testing platinum-based chemotherapy in triple-negative breast cancer … dundee council change of address